NICEVIVA
MONOGRAPH SPEC LATEST 2026

Rosemary Extract

BOTANICALS · Evidence Monograph

Rosemary Extract is an evidence-graded botanicals monograph evaluated across 35 peer-reviewed PubMed studies (0 meta-analyses, 0 systematic reviews, and 6 randomized controlled trials, encompassing n = 1,127 cumulative participants). Current clinical evidence is rated GRADE Moderate (3.0 / 4.0) for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

Evidence Grade (GRADE) Moderate (3.0 / 4.0)
Indexed PubMed Studies 35 Studies
Meta-Analyses · Reviews 0 Meta · 0 Systematic Reviews
Randomized Trials (RCT) 6 RCTs (4 Double-Blind)
Cumulative Participants n = 1,127
Reported Trial Dosages 25 μg · 3 g · 80 mg
Trial Duration Range 5 days · 6 days · 12 weeks
Reading Time ~18 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways (supported by 35 indexed PubMed studies, GRADE Moderate).
  2. 02 Adults matching clinical trial dosing protocols (25 μg · 3 g · 80 mg) over a structured 5 days evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Standardized Marker-Compound Botanical Extract
Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.
Dose Adjustment Signal: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
Immediately After Breakfast or Lunch
Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
cancer (PubMed clinical endpoint)
antioxidant (PubMed clinical endpoint)
alopecia (PubMed clinical endpoint)
hair (PubMed clinical endpoint)
01

What Is Rosemary Extract & Why Does Form Matter?

Rosemary Extract is classified under BOTANICALS and has been investigated across 35 peer-reviewed PubMed publications for its role in phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (25 μg, 3 g, 80 mg).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Rosemary Extract frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (6 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Rosemary Extract acts on pathways governing phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Rosemary Extract an overall evidence rating of GRADE Moderate (3.0 / 4.0) based on 35 PubMed studies: 0 meta-analyses, 0 systematic reviews, and 6 randomized controlled trials (4 double-blind, n = 1,127 total participants).

Representative peer-reviewed findings include: • PMID:39528839 (2025) — "Scalp condition improvement with botanical extracts possessing chemical and physical antioxidant activity." (CONCLUSION: Improved scalp condition can be achieved with incorporation of botanicals having the potential to exert antioxidant activity in hair/scalp care products.) • PMID:40467212 (2025) — "Comparative study of rosemary extract, TBHQ, citric acid and their composite antioxidants on the overall quality of peanuts and evaluation of their synergistic antioxidant properties and interaction." (These findings offer valuable insights for optimizing processing and preservation technologies for peanuts and their products.) • PMID:27484718 (2016) — "Effects and synergy of feed ingredients on canine neoplastic cell proliferation." (CONCLUSIONS: The use of turmeric and rosemary extracts in combination may be worthwhile to investigate in the pre-clinical and clinical neoplastic considering there are no negative effects on traditional chemotherapy treatment.)

05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Standardized Marker-Compound Botanical Extract. Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 25 μg · 3 g · 80 mg · 200 mg over 5 days · 6 days · 12 weeks · 90 days. Optimal timing window: PM 12:30 · Immediately After Breakfast or Lunch (Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.

Adjustment & Discontinuation Signals: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Rosemary Extract, but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · Immediately After Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (25 μg · 3 g · 80 mg) and re-evaluate efficacy after 5 days.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (35 Studies) · 8 Quantitative Analyses

01
CLINICAL STUDY International journal of cosmetic science (2025) PMID: 39528839 ↗
Scalp condition improvement with botanical extracts possessing chemical and physical antioxidant activity.
Clinical Trial Synthesis 2025 Clinical Study published in International journal of cosmetic science. Key conclusion: CONCLUSION: Improved scalp condition can be achieved with incorporation of botanicals having the potential to exert antioxidant activity in hair/scalp care products.
View Original PubMed Abstract ↓

OBJECTIVE: Oxidative stress is implicated in scalp and hair health manifesting in several ways, including skin barrier, hair retention, healthy hair appearance and scalp sensation. We previously linked markers of oxidative damage to dandruff and skin barrier impairment and have linked key anti-dandruff technologies to the resolution of these issues. Here we expand the therapeutic space demonstrating many botanical extracts offer protective benefits against ROS stress via both chemical and biological antioxidant mechanisms. METHODS: Chemical antioxidant activity of 10 botanical extracts was measured using oxygen radical absorbance capacity (ORAC) and biological antioxidant activity was measured using a Nrf-2 cell assay. A three-dimensional human keratinocyte skin equivalent model from MatTek was used to measure efficacy of reducing reactive oxygen species (ROS) from both the botanicals added as a solution and from a shampoo product. A 4-week consumer study with 56 panels was conducted with a leave-on treatment containing a botanical extract. Measurement of the oxidized lipids (9 and 13-Hydroxy-10E 12Z-octadecadienoic acid, HODE) extracted from scalp tape strips was made using gradient reversed-phase high-performance liquid chromatography with tandem mass spectrometry (HPLC/MS/MS). RESULTS: We demonstrated in vitro that many botanical extracts exert antioxidant activity by quenching radicals in ORAC testing as well as activating biological antioxidant pathways via nrf-2 up-regulation in a cellular reporter system. Furthermore, we demonstrate these antioxidant activities for these botanicals in 3D skin models and ultimately show the reduction of lipid oxidation products in a consumer use context with a rosemary extract. CONCLUSION: Improved scalp condition can be achieved with incorporation of botanicals having the potential to exert antioxidant activity in hair/scalp care products. Publisher: OBJECTIF: Le stress oxydatif est impliqué dans la santé du cuir chevelu et des cheveux et se manifeste de plusieurs manières, notamment la barrière cutanée, la rétention des cheveux, l'apparence saine des cheveux et la sensation du cuir chevelu. Nous avons précédemment lié l

02
CLINICAL STUDY Food research international (Ottawa, Ont.) (2025) PMID: 40467212 ↗
Comparative study of rosemary extract, TBHQ, citric acid and their composite antioxidants on the overall quality of peanuts and evaluation of their synergistic antioxidant properties and interaction.
Clinical Trial Synthesis 2025 Clinical Study published in Food research international (Ottawa, Ont.). Key conclusion: These findings offer valuable insights for optimizing processing and preservation technologies for peanuts and their products.
View Original PubMed Abstract ↓

Peanut is an important raw material of many kinds of food, its lipids and proteins content are high, antioxidant is important to the shelf life and quality of peanut products. The present study investigated the effects of rosemary extract (RE), tert-butylhydroquinone (TBHQ), and citric acid (CA) as individual additives, as well as their combinations (RE-TBHQ and RE-TBHQ-CA) on the quality characteristics and antioxidant properties of peanuts. All antioxidant treatment methods modified the physicochemical properties and bioactive compounds of peanuts, including flavor, color, texture and appearance. Additionally, the synergistic effects of the combined antioxidants RE-TBHQ-CA were explored. Notably, RE-TBHQ-CA with a concentration of 0.02 % resulted in highest oxidation induction index of peanut oil compared to the control and demonstrated optimal effects on free radical scavenging activity. Based on fluorescence quenching, cyclic voltammetry measurements, and the oxidative decomposition of antioxidants during storage, it was proposed that TBHQ's stimulatory effect on RE regeneration is responsible for the observed synergism. These findings offer valuable insights for optimizing processing and preservation technologies for peanuts and their products.

03
CLINICAL STUDY BMC veterinary research (2016) PMID: 27484718 ↗
Effects and synergy of feed ingredients on canine neoplastic cell proliferation.
Clinical Trial Synthesis 2016 Clinical Study published in BMC veterinary research. Key conclusion: CONCLUSIONS: The use of turmeric and rosemary extracts in combination may be worthwhile to investigate in the pre-clinical and clinical neoplastic considering there are no negative effects on traditional chemotherapy treatment.
View Original PubMed Abstract ↓

BACKGROUND: Adjunctive use of nutraceuticals in human cancer has shown promise, but little work has been done in canine neoplasia. Previous human research has shown that polyphenols and carotenoids can target multiple pathways in vitro and in vivo. These compounds could synergize or antagonize with currently used chemotherapies, either increasing or decreasing the effectiveness of these drugs. Considering the routine and well controlled feeding practices of most dogs, the use of nutraceuticals incorporated into pet food is attractive, pending proof that the extracts are able to improve remission rates. The aim of this study was to examine five feed ingredients for antiproliferative effects, as well as the interaction with toceranib phosphate and doxorubicin hydrochloride, when treating canine neoplastic cell lines in vitro. RESULTS: Screening using MTT proliferation assays showed that green tea, turmeric, and rosemary extracts were the most effective. Turmeric extract (TE) was the most potent and exhibited synergy with a rosemary extract (RE) at concentrations from 1 to 25 μg mL(-1). This combination had an additive or synergistic effect with chemotherapeutic agents at selected concentrations within each cell line. No significant effects on cell viability were observed when the combination therapy was used with normal primary cells. CONCLUSIONS: The use of turmeric and rosemary extracts in combination may be worthwhile to investigate in the pre-clinical and clinical neoplastic considering there are no negative effects on traditional chemotherapy treatment. Further studies into the pharmacokinetics and mechanisms of action of these extracts should be investigated.

04
CLINICAL STUDY Nutrition and cancer (2015) PMID: 26452641 ↗
Rosemary (Rosmarinus officinalis L.) Extract as a Potential Complementary Agent in Anticancer Therapy.
Clinical Trial Synthesis 2015 Clinical Study published in Nutrition and cancer. Key conclusion: The possibility of using rosemary extract as a complementary agent in cancer therapy in comparison with its isolated components is discussed.
View Original PubMed Abstract ↓

Cancer remains an important cause of mortality nowadays and, therefore, new therapeutic approaches are still needed. Rosemary (Rosmarinus officinalis L.) has been reported to possess antitumor activities both in vitro and in animal studies. Some of these activities were attributed to its major components, such as carnosic acid, carnosol, ursolic acid, and rosmarinic acid. Initially, the antitumor effects of rosemary were attributed to its antioxidant activity. However, in recent years, a lack of correlation between antioxidant and antitumor effects exerted by rosemary was reported, and different molecular mechanisms were related to its tumor inhibitory properties. Moreover, supported by the U.S. Food and Drug Administration and the European Food and Safety Authority, specific compositions of rosemary extract were demonstrated to be safe for human health and used as antioxidant additive in foods, suggesting the potential easy application of this agent as a complementary approach in cancer therapy. In this review, we aim to summarize the reported anticancer effects of rosemary, the demonstrated molecular mechanisms related to these effects and the interactions between rosemary and currently used anticancer agents. The possibility of using rosemary extract as a complementary agent in cancer therapy in comparison with its isolated components is discussed.

05
CLINICAL STUDY Pharmacological research (2013) PMID: 23557932 ↗
Antitumor effect of 5-fluorouracil is enhanced by rosemary extract in both drug sensitive and resistant colon cancer cells.
Clinical Trial Synthesis 2013 Clinical Study published in Pharmacological research. Key conclusion: Gene expression analysis indicates that the enhancement of the effect of 5-FU by SFRE might be explained by the downregulation of TYMS and TK1, enzymes related to 5-FU resistance.
View Original PubMed Abstract ↓

5-Fluorouracil (5-FU) is the most used chemotherapeutic agent in colorectal cancer. However, resistance to this drug is relatively frequent, and new strategies to overcome it are urgently needed. The aim of this work was to determine the antitumor properties of a supercritical fluid rosemary extract (SFRE), alone and in combination with 5-FU, as a potential adjuvant therapy useful for colon cancer patients. This extract has been recognized as a healthy component by the European Food Safety Authority (EFSA). The effects of SFRE both alone and in combination with 5-FU were evaluated in different human colon cancer cells in terms of cell viability, cytotoxicity, and cell transformation. Additionally, colon cancer cells resistant to 5-FU were used to assay the effects of SFRE on drug resistance. Finally, qRT-PCR was performed to ascertain the mechanism by which SFRE potentiates the effect of 5-FU. Our results show that SFRE displays dose-dependent antitumor activities and exerts a synergistic effect in combination with 5-FU on colon cancer cells. Furthermore, SFRE sensitizes 5-FU-resistant cells to the therapeutic activity of this drug, constituting a beneficial agent against both 5-FU sensitive and resistant tumor cells. Gene expression analysis indicates that the enhancement of the effect of 5-FU by SFRE might be explained by the downregulation of TYMS and TK1, enzymes related to 5-FU resistance.

06
CLINICAL STUDY Journal of the science of food and agriculture (2011) PMID: 21218479 ↗
Synergistic antimicrobial activity of galangal (Alpinia galanga), rosemary (Rosmarinus officinalis) and lemon iron bark (Eucalyptus staigerana) extracts.
Clinical Trial Synthesis 2011 Clinical Study published in Journal of the science of food and agriculture. Key conclusion: CONCLUSION: The results of this study show that galangal, rosemary and lemon iron bark extracts contain components that may have different modes of antimicrobial action and combinations of these extracts may have potential as natural antimicrobials to preserve foods.
View Original PubMed Abstract ↓

BACKGROUND: In this study the synergistic antimicrobial activities of combinations of extracts from galangal (Alpinia galanga), rosemary (Rosmarinus officinalis) and lemon iron bark (Eucalyptus staigerana) were evaluated against Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, Salmonella typhimurium and Clostridium perfringens. Chemical compositions of these extracts were also determined to provide further insight into antimicrobial constituents and their potential mechanisms of action. RESULTS: Combinations of galangal with either rosemary or lemon iron bark showed synergistic antimicrobial activity. Specifically, galangal and rosemary showed synergistic activity against S. aureus and L. monocytogenes only, while galangal and lemon iron bark showed synergistic activity against E. coli and S. typhimurium. Chemical compositions of the extracts were determined by gas chromatographic-mass spectrometric analysis. The major chemical components of the galangal and lemon iron bark extracts were 1'-acetoxy-chavicol acetate (1'ACA) (63.4%) and neral (15.6%), respectively, while 1,8-cineole (26.3%) and camphor (20.3%) were identified as major chemical components of the rosemary extract. CONCLUSION: The results of this study show that galangal, rosemary and lemon iron bark extracts contain components that may have different modes of antimicrobial action and combinations of these extracts may have potential as natural antimicrobials to preserve foods. 2010 Society of Chemical Industry.

07
CLINICAL STUDY Oncology (2008) PMID: 18852491 ↗
Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia.
Clinical Trial Synthesis 2008 Clinical Study published in Oncology. Key conclusion: CONCLUSION: Combined effectiveness of 1,25D(3) analogues and rosemary agents against mouse AML warrants further exploration of this therapeutic approach in translational models of human leukemia.
View Original PubMed Abstract ↓

OBJECTIVE: Differentiation therapy with the hormonal form of vitamin D, 1alpha,25-dihydroxyvitamin D(3) (1,25D(3)), is a promising approach to treatment of acute myeloid leukemia (AML); however, 1,25D(3) induces hypercalcemia at pharmacologically active doses. We investigated the in vitro and in vivoantileukemic efficacy of combined treatment with non-toxic doses of a low-calcemic 1,25D(3) analogue, 1,25-dihydroxy-21(3-hydroxy-3-methyl-butyl)-19-nor-cholecalciferol (19-nor-Gemini; Ro27-5646), and rosemary plant agents in a mouse model of AML. METHODS: Proliferation and differentiation of WEHI-3B D- (WEHI) murine myelomonocytic leukemia cellsin vitro were determined by standard assays. Reactive oxygen species, glutathione and protein expression levels were measured by flow cytometry, enzymatic assay and Western blotting, respectively. Systemic AML was developed by intravenous injection of WEHI cells in syngeneic Balb/c mice. RESULTS: 19-nor-Gemini had a higher potency than its parent compounds, Gemini (Ro27-2310) and 1,25D(3), in the induction of differentiation (EC(50) = 0.059 +/- 0.011, 0.275 +/- 0.093 and 0.652 +/- 0.085 nM, respectively) and growth arrest (IC(50) = 0.072 +/- 0.018, 0.165 +/- 0.061 and 0.895 +/- 0.144 nM, respectively) in WEHI cells in vitro, and lower in vivo toxicity. Combined treatment of leukemia-bearing mice with 19-nor-Gemini (injected intraperitoneally) and standardized rosemary extract (mixed with food) resulted in a synergistic increase in survival (from 42.2 +/- 2.5 days in untreated mice to 66.5 +/- 4.2 days, n = 3) and normalization of white blood cell and differential counts. This was consistent with strong cooperative antiproliferative and differentiation effects of low concentrations of 19-nor-Gemini or 1,25D(3) combined with rosemary extract or its major polyphenolic component, carnosic acid, as well as with the antioxidant action of rosemary agents and vitamin D derivatives in WEHI cell cultures. CONCLUSION: Combined effectiveness of 1,25D(3) analogues and rosemary agents against mouse AML warrants further exploration of this therapeutic approach in translational models of human leukemia. Copyright 2008 S. Karger AG, Basel.

08
CLINICAL STUDY International journal of cancer (2006) PMID: 16395705 ↗
Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia.
Clinical Trial Synthesis 2006 Clinical Study published in International journal of cancer. Key conclusion: injections of 2 microg Ro25-4020 in Balb/c mice bearing WEHI-3B D(-) tumors produced a significant delay in tumor appearance and reduction in tumor size, without significant toxicity.
View Original PubMed Abstract ↓

1alpha,25-dihydroxyvitamin D(3) (1,25D(3)) is a powerful differentiation agent, which has potential for treatment of myeloid leukemias and other types of cancer, but the calcemia produced by pharmacologically active doses precludes the use of this agent in the clinic. We have shown that carnosic acid, the major rosemary polyphenol, enhances the differentiating and antiproliferative effects of low concentrations of 1,25D(3) in human myeloid leukemia cell lines (HL60, U937). Here we translated these findings to in vivo conditions using a syngeneic mouse leukemia tumor model. To this end, we first demonstrated that as in HL60 cells, differentiation of WEHI-3B D(-) murine myelomonocytic leukemia cells induced by 1 nM 1,25D(3) or its low-calcemic analog, 1,25-dihydroxy-16-ene-5,6-trans-cholecalciferol (Ro25-4020), can be synergistically potentiated by carnosic acid (10 microM) or the carnosic acid-rich ethanolic extract of rosemary leaves. This effect was accompanied by cell cycle arrest in G0 + G1 phase and a marked inhibition of cell growth. In the in vivo studies, i.p. injections of 2 microg Ro25-4020 in Balb/c mice bearing WEHI-3B D(-) tumors produced a significant delay in tumor appearance and reduction in tumor size, without significant toxicity. Another analog, 1,25-dihydroxy-16,23Z-diene-20-epi-26,27-hexafluoro-19-nor-cholecalciferol (Ro26-3884) administered at the same dose was less effective than Ro25-4020 and profoundly toxic. Importantly, combined treatment with 1% dry rosemary extract (mixed with food) and 1 microg Ro25-4020 resulted in a strong cooperative antitumor effect, without inducing hypercalcemia. These results indicate for the first time that a plant polyphenolic preparation and a vitamin D derivative can cooperate not only in inducing leukemia cell differentiation in vitro, but also in the antileukemic activity in vivo. These data may suggest novel protocols for chemoprevention or differentiation therapy of myeloid leukemia. Copyright 2006 Wiley-Liss, Inc.

09
CLINICAL STUDY Journal of food protection (2000) PMID: 11041135 ↗
Antimicrobial effect of rosemary extracts.
Clinical Trial Synthesis 2000 Clinical Study published in Journal of food protection. Key conclusion: Lipids, surface-active agents, and some proteins decreased its antibacterial activity, whereas pectin had no effect.
View Original PubMed Abstract ↓

A rosemary extract commercially exploited (Oxy'less) as an antioxidant of lipids in foods was dissolved in ethanol (100 mg/ml), and the solution was tested against foodborne microorganisms. For gram-positive bacteria, the MIC of the ethanolic solution was 1% for Leuconostoc mesenteroides, 0.5% for Listeria monocytogenes, 0.5% for Staphylococcus aureus, 0.13% for Streptococcus mutans, and 0.06% for Bacillus cereus. It slowed the growth of Penicillium roquefortii and Botrytis cinerea. Up to 1% of the ethanolic solution had no activity on the gram-negative bacteria Escherichia coli, Salmonella Enteritidis, and Erwinia carotovora and on the yeasts Rhodotorula glutinis and Cryptococcus laurentii. Antibacterial activity of the rosemary extract was strongly influenced by the composition of the media. The MIC was reduced by low pH, high NaCl contents, and low temperatures. Low pH and high NaCl concentration had a synergistic effect on the MIC of the rosemary extract for S. aureus. Lipids, surface-active agents, and some proteins decreased its antibacterial activity, whereas pectin had no effect. The inhibitory effect was little modified by heat treatment (100 degrees C). The natural microflora of pasteurized zucchini broth was inhibited by 0.5% of the rosemary extract. The antibacterial activity was linked to the compounds extracted with hexane, which are presumably phenolic diterpenoids.

10
CLINICAL STUDY Urologiia (Moscow, Russia (2025) PMID: 40377579 ↗
[Results of treatment of acute uncomplicated cystitis in 440 women of working age in a large industrial city].
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Urologiia (Moscow, Russia involving n = 440 participants. Key conclusion: However, results were significantly better in groups 3 and 4, with rapid resolution of pain, dysuria, and other symptoms.
View Original PubMed Abstract ↓

INTRODUCTION: Lower urinary tract infections (UTIs) affect nearly two-thirds of all women during their lifetime, and many suffer from recurrent infections. There are evidence-based guidelines from several international societies and RSU for the evaluation and treatment of UTIs; however, adherence to these guidelines is not always optimal. AIM: To study the immediate outcomes of treating acute uncomplicated cystitis in working-age women living in a large industrial city under unfavorable environmental and climatic conditions. MATERIALS AND METHODS: A multicenter, randomized, open-label study was carried out in 4 outpatient clinics in Perm involving 440 women with acute uncomplicated cystitis. Depending on the treatment, the patients were divided into 4 groups. The main drug was the antibiotic fosfomycin trometamol, which was given at a single dose of 3 g to all 440 patients. In the group 1, monotherapy with fosfomycin trometamol was used. Patients in groups 2-4 received basic antibacterial therapy (3 g of fosfomycin trometamol), supplemented with symptomatic and herbal remedies. In the group 2, drotaverine was used at 80 mg 3 times a day for 2 days, in the group 3 phenazopyridine at a dose of 200 mg 3 times a day for 2 days was given, while in the group 4, Canephron N at 2 tablets 3 times a day for 6 days was administered. The symptoms of cystitis were assessed using the ACSS scale, visual analog scale (VAS) of pain, urinalysis with microscopic examination of urinary sediment, bacteriological examination of urine and other methods. The results were assessed after 6, 12, 24, 48 hours, 3 and 6 days. RESULTS: The sensitivity of microorganisms to fosfomycin in bacteriological studies was 97.2%. In group 1, recovery was achieved in 92.5%, improvement in 6.6%, and the bacteriological cure was 95.3%; however, the ACSS and VAS scales indicated insufficiently rapid elimination of pain and other symptoms. In the group 2, improvement in results was insignificant. However, results were significantly better in groups 3 and 4, with rapid resolution of pain, dysuria, and other symptoms. In group 3, recovery was achieved in 97.3%, bacteriological cure and disability period were

RELATED MONOGRAPHS

Related Monographs in This Category